Glenmark collaborates with SCD for Ophthalmic products in U.S and Canada

Global pharmaceutical company, Glenmark Pharmaceuticals ventured into an exclusive agreement with Sam Chun Dang Pharma. Co. Ltd. (SCD) to develop, manufacture and market a portfolio of ophthalmic products in the U.S and Canada. As per the terms of the agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorizations and commercialize products in North America.

Robert Matsuk, President, North America & Global API at Glenmark Pharmaceuticals said  “Our strategic partnership with SCD supports our objective to expand the product offerings of our complex generic portfolio.”

Glenmark will file six Abbreviated New Drug Applications (ANDAs) beginning in the first half of 2019 for the licensed SCD ophthalmic products. According to IMS sales figures, the U.S. brand sales for the six products was approximately $1.7 billion for calendar year 2017.